An APE1 Redox Inhibitor Attenuates Pathological Retinal Vascularization by Suppressing FGF2 Angiogenic Signaling

Key Points

• The research aims to evaluate the effects of APE1 redox inhibitor Refi-10 on retinal vascularization and FGF2 signaling.
• Assessment of APE1 and FGF2 signaling pathways
• Evaluation of Refi-10 effects on retinal vascularization
• Comparison of Refi-10 with VEGF inhibition
• Refi-10 significantly attenuates pathological retinal vascularization
• Suppression of FGF2 signaling correlates with reduced vascularization
• Findings support APE1 and FGF2 as therapeutic targets for vascular retinopathies

Abstract